Abstract:
:Hereditary pancreatitis shares a majority of clinical and morphologic features with chronic alcoholic pancreatitis, but may present at an earlier age. The term hereditary pancreatitis has primarily been associated with mutations in the serine protease 1 gene (PRSS1) which encodes for cationic trypsinogen. PRSS1 mutations account for approximately 68-81% of hereditary pancreatitis. Mutations in other genes, primarily serine protease inhibitor Kazal type 1 (SPINK1) and the cystic fibrosis transmembrane conductance regulator (CFTR) are also associated with hereditary pancreatitis. While chronic alcoholic pancreatitis may develop in the fourth or fifth decades, patients with hereditary pancreatitis may develop symptoms in the first or second decades of life. Hereditary pancreatitis is diagnosed either by detecting a causative gene mutation or by the presence of chronic pancreatitis in two first-degree or three second-degree relatives, in two or more generations, without precipitating factors and with a negative workup for known causes. Patients with hereditary pancreatitis may have recurrent acute pancreatitis and may develop pancreatic exocrine and endocrine insufficiency. Hereditary pancreatitis may involve premature trypsinogen activation or decreased control of trypsin. Recurrent inflammation can lead to acute pancreatitis and subsequently to chronic pancreatitis with parenchymal calcification. There is a markedly increased risk of pancreatic carcinoma compared with the general population. Patients are often referred for evaluation of pancreatitis, biliary or pancreatic ductal dilatation, jaundice, biliary obstruction, pancreatic duct stone or stricture, pancreatic pseudocysts, and for evaluation for malignancy. Medical treatment includes pancreatic enzyme supplementation, nutritional supplementation, diabetes management, and palliation of pain. Patients should avoid tobacco use and alcohol exposure. Hereditary pancreatitis is reviewed and recommendations for genetic testing are discussed.
journal_name
Therap Adv Gastroenteroljournal_title
Therapeutic advances in gastroenterologyauthors
Patel MR,Eppolito AL,Willingham FFdoi
10.1177/1756283X12467565subject
Has Abstractpub_date
2013-03-01 00:00:00pages
169-79issue
2eissn
1756-283Xissn
1756-2848pii
10.1177_1756283X12467565journal_volume
6pub_type
杂志文章abstract:METHODS:Suboptimal bowel preparation, present in over 20% of colonoscopies, can severely compromise the effectiveness of the colonoscopy procedure. We surveyed 93 primarily urban minority men and women who underwent asymptomatic 'screening' colonoscopy regarding their precolonoscopy bowel-preparation experience. RESUL...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X13498661
更新日期:2013-11-01 00:00:00
abstract:Background:In patients with a large, unresectable hepatocellular carcinoma (HCC), the primary recommendation is for transarterial chemoembolization (TACE) but used alone TACE is not typically curative. Combinations of TACE followed in a delayed fashion by single-applicator thermal ablation have also been suboptimal. As...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819862966
更新日期:2019-08-21 00:00:00
abstract::In 2010, four independent groups almost simultaneously reported the association of the novel interleukin-1 (IL-1) family member, IL-33, with inflammatory bowel disease (IBD). The findings were remarkably consistent and demonstrated that IL-33 is markedly upregulated in, and specific to, ulcerative colitis (UC). In add...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11410770
更新日期:2011-09-01 00:00:00
abstract::Erratum to 'Possible interactions between dietary fibres and 5-aminosalicyclic acid' by C Henriksen, S Hansen, I Nordgaard-Lassen, J Rikardt Anderson and P Madsen. Therapeutic Advances in Gastroenterology (2010) 3(1) 5-9 [DOI: 10.1177/ 1756283X09347810][This corrects the article on p. 5 in vol. 3.]. ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 已发布勘误
doi:10.1177/1756283X10363751
更新日期:2012-09-01 00:00:00
abstract::Hepatocellular carcinoma (HCC) is a common and serious health problem with high mortality. Treatment for HCC remains largely unsatisfactory owing to its high recurrence rates and frequent accompanying cirrhosis. In addition, the unique immune environment of the liver promotes tolerance, which, in conjunction with immu...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X17722061
更新日期:2017-10-01 00:00:00
abstract:Background:The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan's demographic structure is becoming pronounced. In this study, we exami...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819858511
更新日期:2019-07-04 00:00:00
abstract::The intestinal microbiota consists of a dynamic organization of bacteria, viruses, archaea, and fungal species essential for maintaining gut homeostasis and protecting the host against pathogenic invasion. When dysregulated, the intestinal microbiota can contribute to colorectal cancer development. Though the microbio...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X17694832
更新日期:2017-05-01 00:00:00
abstract::Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple cli...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X16638833
更新日期:2016-07-01 00:00:00
abstract::Atrial fibrillation (AF) is the most common arrhythmia worldwide and is associated with significant morbidity and mortality. A number of risk factors have been associated with AF, though few studies have explored the association between gastrointestinal and liver diseases and AF. Additionally, AF and treatment for AF ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284819832237
更新日期:2019-04-02 00:00:00
abstract:BACKGROUND:Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR12). The incidence of EOT+/SVR in patients with genotype 1 and...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16672392
更新日期:2017-01-01 00:00:00
abstract:Background:Recurrent Clostridium difficile infection (rCDI) is becoming increasingly common. Faecal microbiota transplantation (FMT) is effective for rCDI, but the costs of an FMT and hospital cost savings related to FMT are unknown. The aim of this study was to calculate the cost of an FMT and the total hospital costs...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819843002
更新日期:2019-04-10 00:00:00
abstract::In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program sug...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11413315
更新日期:2011-11-01 00:00:00
abstract::The treatment of hepatocellular carcinoma (HCC) remains a challenge, with 1- and 3-year survival rates of 20% and 5%, respectively, and a median survival of 8 months. However, a better understanding of the pathogenesis of HCC, and advances in targeted molecular therapies provide physicians treating this disease with n...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09346669
更新日期:2010-01-01 00:00:00
abstract::Crohn's disease (CD) is a chronic relapsing and remitting disorder of the gastrointestinal tract with no known cure. The inflammation that drives the disease can lead to debilitating symptoms and a number of complications that may lead to surgery. The introduction of biologic therapy a decade ago has offered a new opt...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09357579
更新日期:2010-05-01 00:00:00
abstract::Several clinical trials and experimental studies strongly suggest a place for Saccharomyces boulardii as a biotherapeutic agent for the prevention and treatment of several gastrointestinal diseases. S. boulardii mediates responses resembling the protective effects of the normal healthy gut flora. The multiple mechanis...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X11428502
更新日期:2012-03-01 00:00:00
abstract:BACKGROUND:Mast cells (MCs) can stimulate angiogenesis, releasing several proangiogenic cytokines stored in their cytoplasm. In particular, MCs can release tryptase, a potent in vivo and in vitro proangiogenic factor via protease-activated receptor-2 (PAR-2) activation and mitogen-activated protein kinase (MAPK) phosph...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X16673981
更新日期:2017-04-01 00:00:00
abstract::Endoscopic argon plasma coagulation and bipolar electrocautery are currently preferred treatments for chronic radiation proctitis, but ulcerations and strictures frequently occur. Radiofrequency ablation (RFA) has been successful for mucosal ablation in the esophagus. Here we report the efficacy of RFA with the BarRx ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283x08103341
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:Endoscopic therapy for early neoplasia in Barrett's esophagus (BE) is evolving. Endoscopic resection has an increasing role. We wanted to evaluate the safety and efficacy of multi-band ligation/resection [ER-L] without pre-injection in BE with high-grade dysplasia [HGD] and intramucosal carcinoma [IMCA]. ME...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X09346794
更新日期:2009-11-01 00:00:00
abstract:Background:Recently the American Society for Gastrointestinal Endoscopy addressed the 'resect and discard' strategy, determining that accurate in vivo differentiation of colorectal polyps (CP) is necessary. Previous studies have suggested a promising application of artificial intelligence (AI), using deep learning in o...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820910659
更新日期:2020-03-20 00:00:00
abstract::Helicobacter pylori (H. pylori) are gram-negative bacteria that selectively colonizes the gastric mucosa. The prevalence of H. pylori infection varies from 20 to 50% in industrialized countries to over 80% in developing countries. The infection may persist lifelong without specific treatment. Prolonged infection and i...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X08094880
更新日期:2008-09-01 00:00:00
abstract::On 31 December 2019, the WHO China Country Office was informed of cases of pneumonia of unknown etiology detected in Wuhan (Hubei Province of China). In January 2020, a new coronavirus named SARS-CoV2 was isolated and, since that time, SARS-CoV2 related disease (COVID-19) rapidly spread all over the world becoming pan...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284820935187
更新日期:2020-06-24 00:00:00
abstract:Background:Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-tr...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284818783614
更新日期:2018-06-21 00:00:00
abstract:Background:Postoperative pancreatic collection (POPC) is a frequent complication after pancreatectomy. Although percutaneous drainage (PD) has been the treatment of choice for POPC with encapsulation, endoscopic ultrasound-guided transmural drainage (EUS-TD) was recently reported effective for this condition. The main ...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284819884418
更新日期:2019-10-24 00:00:00
abstract::Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver diseases and hepatocellular carcinoma (HCC) worldwide. In the past few years, anti-HCV therapies have undergone a revolution with the approval of multiple direct-acting antivirals (DAAs), which enable interferon-free treatments with consider...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284818759483
更新日期:2018-03-21 00:00:00
abstract::Chronic hepatitis C (CHC) affects over 185 million individuals worldwide, approximately 3% of the world's population. CHC can lead to quality of life impairment, cirrhosis, hepatocellular carcinoma (HCC), liver failure and liver-related death. While CHC has been associated with increases in HCC, liver-related mortalit...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756283X15587481
更新日期:2015-09-01 00:00:00
abstract:Background and Aims:Efficacy of adalimumab in Crohn's disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. Methods:This 26-week, multicenter, phase III study evaluated patients with moderately to severely active CD and elevat...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284820938960
更新日期:2020-07-16 00:00:00
abstract:Introduction:Hepatocholangiocarcinoma (HCC-ICC) is a rare tumor presenting the histologic characteristics of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). As there is no consensus on it management, the therapeutic strategy rests on the specific treatments for HCC or ICC. Programmed cell...
journal_title:Therapeutic advances in gastroenterology
pub_type:
doi:10.1177/1756284820935189
更新日期:2020-06-20 00:00:00
abstract::The wireless motility capsule (WMC) is an ambulatory noninvasive and nonradioactive diagnostic sensor that continuously samples intraluminal pH, temperature, and pressure as it moves through the gastrointestinal (GI) tract. This review summarizes the data obtained in clinical trials with the WMC and discusses its role...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756283X12437874
更新日期:2012-07-01 00:00:00
abstract::Portal hypertension represents one of the major clinical consequences of chronic liver disease, having a deep impact on patients' prognosis and survival. Its pathophysiology defines a pathological increase in the intrahepatic vascular resistance as the primary factor in its development, being subsequently aggravated b...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章,评审
doi:10.1177/1756284818811294
更新日期:2018-11-25 00:00:00
abstract:Objective:i-Scan is a digital image enhancement technology, reported to improve diagnostic performance during endoscopy. Previous studies have investigated the accuracy of i-scan for distinguishing between neoplastic and non-neoplastic colonic polyps and suggested diagnostic accuracy close to that required for use in r...
journal_title:Therapeutic advances in gastroenterology
pub_type: 杂志文章
doi:10.1177/1756284818814948
更新日期:2018-12-06 00:00:00